Non-cash 'payment' enough for pay-for-delay case, Third Circuit says in Lamictal case
Makers of brand-name drugs that offer payments to generics rivals can run afoul of antitrust law even if those payments are not in cash, the US Court of Appeals for the Third...To view the full article, register now.
Already a subscriber? Click here to view full article